Loeillot Olivier 4

4 · REPLIGEN CORP · Filed Mar 23, 2026

AI-generated summary of this filing

Updated Mar 23, 2026

Repligen (RGEN) CEO Olivier Loeillot Receives RSU & Option Awards

What Happened

Olivier Loeillot, Chief Executive Officer of Repligen Corporation (RGEN), received equity awards on March 5, 2026: 24,134 restricted stock units (RSUs) and 25,890 derivative awards (option-type). Both grants are reported as acquisitions at $0.00 (no cash paid at grant).

Key Details

Transaction date: March 5, 2026. Filing date (Form 4): March 23, 2026 (filed 18 days after the transaction).
Award amounts and reported values: 24,134 RSUs @ $0.00; 25,890 derivative/option-type awards @ $0.00.
Vesting schedule:
- RSUs: Vest in equal annual installments over three years beginning on the first anniversary of the grant (per footnote F1). RSUs will be settled only by delivery of common stock.
- Derivative awards/options: One-third vests and becomes exercisable each year on March 5, 2027, 2028 and 2029 (per footnote F2).
Shares owned after the transaction: not specified in the provided filing excerpt.
Filing timeliness: The Form 4 was filed well after the standard two-business-day deadline for insiders — the late filing may be noted on the Form 4 and is relevant for disclosure timeliness.

Context

These grants are compensation awards (not open-market purchases or sales). RSUs convert to actual shares as they vest; the derivative awards appear to be option-type awards that will vest over three years.
Awards do not require immediate cash outlay by the insider; they represent future equity potential contingent on vesting and, for options, exercise. They are routine executive compensation and should be interpreted as such rather than a direct market buy/sell signal.

Form 4

Period: 2026-03-05

Chief Executive Officer

Transactions

Award
Common Stock
[F1]
2026-03-05+24,134→ 58,078 total
Award
Stock Option (Right to Buy)
[F2]
2026-03-05+25,890→ 25,890 total
Exercise: $141.91Exp: 2036-03-05→ Common Stock (25,890 underlying)

Footnotes (2)

[F1]Mr. Loeillot was awarded 24,134 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
[F2]One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.

Signature

/s/ Jennifer Carmichael (Attorney in Fact)|2026-03-23

1 file